Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gilead Sciences Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD), Viatris (VTRS) and Insmed (I...

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Viatris (VTRS) and Insmed (INSM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD) and ENDRA Life Sciences (NDRA...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Cantor Fitzgerald analyst Carter Gould maintained a Buy rating on Gilead Sciences on April 5 and set a price target of $155.00. According to TipRan...

Gilead Sciences (GILD) Gets a Buy from Cantor Fitzgerald

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences on April 3 and set a price target of $160.00. According to TipRanks, Br...

Gilead Sciences (GILD) Receives a Buy from Bernstein

Anthropic, the artificial intelligence (AI) firm behind Claude, has just bought a small biotech startup called Coefficient Bio for about $400 milli...

Anthropic Finalizes $400 Million Takeover of AI Startup Coefficient Bio

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Centene (CNC), Eli Lilly & Co (LLY) and Gilead Scien...

Analysts’ Top Healthcare Picks: Centene (CNC), Eli Lilly & Co (LLY)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN), Apogee Therapeutics (APGE) and Gilead Sciences (GIL...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Apogee Therapeutics (APGE) and Gilead Sciences (GILD)

Scotiabank analyst Louise Chen maintained a Buy rating on Gilead Sciences today and set a price target of $177.00. According to TipRanks, Chen is a...

Scotiabank Reaffirms Their Buy Rating on Gilead Sciences (GILD)

Gilead Sciences ($GILD) has agreed to acquire privately held biotech firm Ouro Medicines in a deal valued at over $2 billion to expand into immunol...

M&A News: Gilead Bets $2B+ on Ouro Medicines to Power Immunology Growth

This article spotlights three ETFs with Outperform ratings and significant upsides, as flagged by TipRanks’ AI analysts.


	A	B	C	D
1	Symbol	Price	Change	Volume
2	GILD	$141.15	+1.69%	2.59M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GILD	$141.15	+1.7%	2.59M
3
4
5
6

GILD

GILD

No Data Available

Get Gilead Sciences Inc. Data in Excel

Get Gilead Sciences Inc. Data in Excel